Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors

Download All
Gain expert perspectives on the evolving role of HER3 in EGFR-mutated advanced NSCLC including the role of HER3-targeted therapies in the setting of EGFR TKI resistance, with this educational program featuring a series of short interactive virtual presentations with downloadable slidesets and a multidisciplinary audio podcast.
person default
Elise Hitron, MSN, FNP-C
Frank Schneider, MD
person default
Conor Ernst Steuer, MD
Helena A. Yu, MD

CME/CE/CPE-Certified Microlearning MedicalMinute Activities

Watch this concise interactive module to gain expert perspective on antibody-drug conjugates and their emerging role in the treatment of lung cancer, including mechanism of action, toxicities, and biomarker selection.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 7, 2022 Expired: February 6, 2023

Download this brief slideset on what an antibody-drug conjugate is, along with how they may fit into the current treatment paradigm for lung cancer.

Helena A. Yu, MD Released: February 7, 2022

Watch this concise interactive module to gain expert perspective on the role of HER3 in lung cancer, including its role in oncogenesis and value as a therapeutic target.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 27, 2021 Expired: October 26, 2022

Download this brief slideset on the role of HER3 in lung cancer along with an introduction to the HER3-targeted antibody–drug conjugate patritumab deruxtecan.

Helena A. Yu, MD Released: October 27, 2021

Watch this concise interactive module to gain a better understanding of resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC and an introduction to ways it is being therapeutically addressed.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 19, 2021 Expired: November 18, 2022

Download this brief slideset on resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC and ways it is being therapeutically addressed.

Helena A. Yu, MD Released: November 19, 2021

Watch this concise interactive module to gain a better understanding of treatment options for patients with advanced EGFR-mutated NSCLC whose disease is resistant to first-line EGFR TKI therapy.

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 19, 2021 Expired: November 18, 2022

Download this brief slideset on treatment options for patients with advanced EGFR-mutated NSCLC whose disease has progressed on first-line EGFR TKI therapy.

Helena A. Yu, MD Released: November 19, 2021

Podcast

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.

person default Elise Hitron, MSN, FNP-C Frank Schneider, MD person default Conor Ernst Steuer, MD Released: January 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings